Liquidia (LQDA) Net Cash Flow Growth (3y) (2023 - 2026)
Liquidia (LQDA) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Liquidia | 6.31 Bn | 6.03 Bn | 160.92 Mn | 128.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.16% |
| Mar 31, 2026 | 205.23% |
| Dec 31, 2025 | 104.79% |
| Sep 30, 2025 | -42.36% |
| Jun 30, 2025 | -46.21% |
| Mar 31, 2025 | -190.06% |
| Dec 31, 2024 | -62.00% |
| Sep 30, 2024 | 174.04% |
| Jun 30, 2024 | -55.19% |
| Mar 31, 2024 | 102.89% |
| Dec 31, 2023 | 36.15% |
| Sep 30, 2023 | -30.33% |
| Jun 30, 2023 | 27.84% |
| Mar 31, 2023 | 27.49% |